Abstract Details

Title Femoral Neuropathy Following Transfemoral Neuroendovascular Procedures. An Analysis of a Prospective Registry

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-043

Objective To study the femoral neuropathy following transfemoral neuroendovascular procedures.

Background Although femoral neuropathy is recognized as an adverse consequence following trans-femoral neuro-endovascular procedures, no reliable estimates are available. We analyzed data from a prospective registry to ascertain the frequency and characteristics of femoral neuropathy following trans-femoral neuro-endovascular procedures.

Design/Methods Consecutive patients who underwent neuro-endovascular procedures through the trans-femoral route were included. Detailed assessment was performed if any patient reportedoccurrence of sensory or motor symptoms in the femoral or lower extremity region including neurological examination (sensory/motor deficits) and femoral region ultrasound.

Results Femoral neuropathy was diagnosed following 4 of 270 neurovascular procedures with an occurrence rate of 1.5% (95% confidence intervals 0.4% – 3.7%). The symptoms were exclusively sensory without any motor involvement. The femoral neuropathy appeared to involve anterior femoral cutaneous nerves in all and medial cutaneous branches in 2 patients, and more than one nerve distribution in one patient in whom lateral cutaneous nerve appeared to be involved. All patients reported resolution of symptoms within a period ranging from 1 week to 2 months. No local hematoma or arterial pseudo-aneurysm was identified at femoral region ultrasound.

Conclusions Femoral neuropathy is a rare occurrence following trans-femoral neuro-endovascular procedures and usually occurs with pure sensory manifestations with complete resolution.

Authors/Disclosures
PRESENTER	No disclosure on file
Muhammad F. Ishfaq, MD	Dr. Ishfaq has nothing to disclose.
Danish Kherani, MD	Dr. Kherani has nothing to disclose.
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.
Laura Qi, MD (University of Minnesota)	No disclosure on file

��ɫ��

��ɫ��